Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir plus ribavirin in adults with genotype 1 or 3 chronic hepatitis C and renal insufficiency
NL-OMON40565Phase 2Withdrawn
- Sponsor
- Gilead Sciences
- Start
- Jan 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sofosbuvir and ribavirin in hepatitis C virus infection (2 arms), sponsored by Gilead Sciences. Primary endpoints: Safety, Pharmacokinetics and 1 more. Planned start Jan 2014; status: withdrawn.
02
Drugs
sofosbuvirribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON40565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40565.